Zacks Research Issues Negative Forecast for MRK Earnings
Research analysts at Zacks Research lowered their Q4 2026 EPS estimates for shares of Merck & Co., Inc. in a report released ...
Zacks.com on MSN12h
Merck (MRK) Stock Moves -0.24%: What You Should Know
The latest trading day saw Merck (MRK) settling at $86.39, representing a -0.24% change from its previous close.
Zacks Research Analysts Decrease Earnings Estimates for MRK
Research analysts at Zacks Research reduced their Q1 2026 EPS estimates for shares of Merck & Co., Inc. in a research note issued to investors on Tuesday, April 1st. Zacks Research analyst S. Ganoria ...
TD Cowen Keeps Their Hold Rating on Merck & Company (MRK)
TD Cowen analyst Steve Scala maintained a Hold rating on Merck & Company (MRK – Research Report) today and set a price target of $100.00.
Merck & Co.: Looming Patent Expiries For Key Drugs Weaken Longer-Term Outlook
Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.
Bernstein Reaffirms Their Hold Rating on Merck & Company (MRK)
Bernstein analyst Courtney Breen maintained a Hold rating on Merck & Company (MRK – Research Report) yesterday and set a price target of ...
Explore more
Forget S&P 500 And Buy These Dividend Icons Instead
Read more on 2 durable dividend stocks that offer higher yields and strong cash flows, outperforming the S&P 500 in value, ...
Yahoo Finance4d
Merck & Co., Inc. (MRK)
But AstraZeneca stock fell in line with pharma stocks. Merck (NYSE:MRK) recently presented promising results from the Phase 3 ZENITH trial for its drug WINREVAIR, but the company's stock ...
How Do Investors Really Feel About Merck & Co?
According to Benzinga Pro, Merck & Co's peer group average for short interest as a percentage of float is 4.19%, which means ...